Cypress Bioscience Inc.
4350 Executive Drive, Suite 325
San Diego
California
92121
United States
Tel: 858-550-6042
Website: http://www.cypressbio.com/
About Cypress Bioscience Inc.
Cypress is a pharmaceutical company dedicated to the development of innovative drugs targeting large unmet medical needs for patients suffering from a variety of disorders of the central nervous system. Since 1999, Cypress has received FDA approvals for both of the products it brought to the FDA during that period, including for Prosorba™, a medical device for rheumatoid arthritis, and Savella® (milnacipran HCl), for fibromyalgia. The Company focuses on generating stockholder value by reaching clinical development milestones as quickly and efficiently as possible. Cypress’ development-stage assets include CYP-1020 for cognitive impairment in schizophrenia, Staccato® nicotine for smoking cessation and intranasal carbetocin for autism. More information on Cypressand its products and development assets is available at www.cypress.com101 articles about Cypress Bioscience Inc.
-
New Cypress Bioscience Inc. Owners Oust Besieged CEO
1/28/2011
-
BioLineRx Ltd. Announces Cypress Bioscience Inc.'s and Royalty Pharma's Commitment to the Development of BL-1020 (CYP-1020) Program
1/25/2011
-
Ramius and Royalty Pharma Announce Successful Conclusion of Cypress Bioscience Inc. Tender Offer
1/6/2011
-
Cypress Bioscience Inc. Release: Federal Trade Commission Grants Early Termination of Waiting Period Under Hart-Scott-Rodino Act
1/4/2011
-
Cypress Bioscience Inc. Agrees To Be Bought By Ramius For Raised $255M Bid
12/15/2010
-
Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience Inc. for $5.50 Per Share
12/10/2010
-
Cypress Bioscience Inc. Announces Third Quarter 2010 Financial Results
11/9/2010
-
Cypress Bioscience Inc. to Present at Oppenheimer 21st Annual Healthcare Conference
11/3/2010
-
Cypress Bioscience Inc. Sells Diagnostics Business Exagen Diagnostics, Inc. for up to $8 Million
10/11/2010
-
Cypress Bioscience Inc. Rejects Raised Ramius Bid, May Sell Assets or Entire Company
9/28/2010
-
Cypress Bioscience Inc. to Present at UBS Global Life Sciences Conference
9/22/2010
-
Ramius Goes Hostile for Cypress Bioscience Inc. with Sweetened Bid
9/15/2010
-
Cypress Bioscience Inc. Acquires Novel Intranasal Carbetocin Therapy for Autism From Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.); Cypress To Pay $750,000 Upfront But Could Give Up To $27 Million More
8/26/2010
-
Alexza Pharmaceuticals, Inc.'s Staccato(R) Nicotine Licensed to Cypress Bioscience Inc.; Cypress Will Pay Alexza An Upfront Payment of $5 Million
8/26/2010
-
Cypress Bioscience Inc. Sends Letter to Ramius; Rejects Offer Again
8/17/2010
-
Ramius May Boost Cypress Bioscience Inc. Bid, Again Blasts Strategy
8/12/2010
-
Cypress Bioscience Inc. Receives Consent for BioLineRx Ltd. In-License Agreement
8/11/2010
-
Cypress Bioscience Inc. Announces Second Quarter 2010 Financial Results
8/9/2010
-
Cypress Bioscience Inc. Rejects Ramius' Buyout Overture
8/6/2010
-
Cypress Bioscience Inc. Ends Savella Co-promotion Deal with Forest Laboratories, Inc.; To Cut 123 Jobs
8/4/2010